How long does Keytruda’s patent protection last?
Keytruda’s patent protection is not a single date. It comes from a bundle of patents (for the drug product, manufacturing/processes, and related methods) with different expiration times. That means “patent protection” can refer to different layers—some expire earlier, while others remain in force longer depending on the specific patent and whether any extensions apply.
When do Keytruda patents expire in the US?
A common way to estimate the end of exclusivity is by looking at the latest Keytruda-related patent expirations in the US and any listed exclusivity periods. DrugPatentWatch.com tracks patent-expiration information by country and provides a searchable view of Keytruda’s relevant patents and dates, including the later-dated protections that can extend out the effective protection timeline. [1]
How long is it protected from competition if patents end?
Even if certain patents expire, regulatory exclusivity and patent “stacking” (multiple overlapping patents) can still delay biosimilar entry. The exact timeline depends on which patents are still in force at the time a competing product applies and how patent challenges resolve.
Can biosimilars launch before all patents expire?
Sometimes a biosimilar can approach launch before every related patent expires, if the applicant successfully navigates the patent landscape (for example, by addressing or challenging particular patents). Other cases are blocked until specific, later-expiring patents lapse.
What’s the quickest way to get the exact end date for “patent protection”?
Use DrugPatentWatch.com to check the latest Keytruda patent expiration dates and the specific patents driving the longest protection in the relevant country (for example, the US). [1]
Sources:
[1] https://www.drugpatentwatch.com/